Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIOยทNYSE

$304.83

+0.14%
HealthcareMedical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

At a Glance

Live Snapshot
Market Cap$8.24B
EPS27.8700
P/E Ratio10.94
Earnings Date07/30/2026

SEC Filings

BIO - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

April 30, 2026
April 30, 2026
2026
10-Q

10-Q 2026 Q1

Q1

April 30, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 24, 2026
April 21, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 25, 2026
April 21, 2026
2026
8-K

8-K 2026

N/A

February 19, 2026
February 19, 2026
2026
10-K

10-K 2025 FY

FY

February 13, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2025

N/A

October 29, 2025
October 29, 2025
2025
10-Q

10-Q 2025 Q3

Q3

October 29, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

September 30, 2025
September 29, 2025
2025
Showing 1 to 10 of 369 filings

Understanding SEC Filings

Essential regulatory documents for investors

SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.

10-K

Annual Report

Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.

Filed annually
10-Q

Quarterly Report

Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.

Filed 3 times per year
8-K

Current Report

Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.

Filed as events occur
DEF 14A

Proxy Statement

Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.

Filed before shareholder meetings
S-1

Registration Statement

Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.

Filed for new offerings
20-F

Foreign Annual Report

Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.

Foreign companies only

Why SEC Filings Matter

  • Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
  • Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
  • Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
  • Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
  • Historical Context: Years of filings provide trend analysis and context for current performance